BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
4.440
+0.020 (0.45%)
At close: Jul 31, 2025, 4:00 PM
4.400
-0.040 (-0.90%)
After-hours: Jul 31, 2025, 4:00 PM EDT

Company Description

BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.

The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.

Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.

It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation.

The company was incorporated in 2015 and is based in Richmond, California.

BioAge Labs, Inc.
BioAge Labs logo
CountryUnited States
Founded2015
IPO DateSep 26, 2024
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees64
CEOKristen Fortney

Contact Details

Address:
1445A South 50th Street
Richmond, California 94804
United States
Phone510 806 1445
Websitebioagelabs.com

Stock Details

Ticker SymbolBIOA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code0001709941
CUSIP Number09077V100
ISIN NumberUS09077V1008
Employer ID47-4721157
SIC Code2834

Key Executives

NamePosition
Dr. Kristen Fortney Ph.D.Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director
Eric Morgen M.D.Co-Founder, Chief Operating Officer and Director
Dr. Paul D. Rubin M.D.Chief Medical Officer and Executive Vice President of Research
Dr. Dov A. Goldstein M.B.A., M.D.Chief Financial Officer
Rusty Montgomery Ph.D.Senior Vice President of Research
Julie GammelgardSenior Vice President of People
Dr. Peng Leong M.B.A., Ph.D.Chief Business Officer and Therapeutic Area Head of Brain Aging
Dr. Carrie-Lynn Langlais FurrSenior Vice President of Regulatory Affairs
Justin ReboSenior Vice President of Translational Aging Biology
BJ Sullivan Ph.D.Chief Strategy Officer

Latest SEC Filings

DateTypeTitle
Jun 9, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 17, 2025ARSFiling
Apr 17, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2025DEF 14AOther definitive proxy statements
Mar 20, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 20, 202510-KAnnual Report
Mar 20, 20258-KCurrent Report